Interventions to reduce antipsychotic polypharmacy

A systematic review

Hideaki Tani, Hiroyuki Uchida, Takefumi Suzuki, Yasuo Fujii, Masaru Mimura

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: It still remains unclear as to how to counteract antipsychotic polypharmacy that remains controversial but common. The objective of this study was to synthesize the clinical evidence to reduce antipsychotic polypharmacy (i.e. use of multiple antipsychotics) in schizophrenia. Methods: A literature search was performed to identify clinical trials that attempted to reduce antipsychotic polypharmacy in patients with schizophrenia by any form of systematic intervention using PubMed as well as MEDLINE, EMBASE, and PsycINFO (last search: June 2012). The search terms included "antipsychotics" and "polypharmacy". Cross-referencing was also performed. Results: The literature search identified 17 studies. Only 3 studies (1 randomized controlled trial and 2 open-label trials) were found that systematically switched antipsychotic polypharmacy to monotherapy. In two of them, more than two thirds of the subjects successfully completed the switch (40/58, 69.0%; 34/44, and 77.3%, respectively) while less than half the subjects tolerated it in the other study (6/14 and 42.9%) although the sample size was very small. On the other hand, 14 studies that examined impacts of interventions have physicians refrain from antipsychotic polypharmacy. While a modest intervention with educational approach alone was effective in three of the five articles, a more assertive intervention that directly cautioned physicians on the use of polypharmacy was effective in 10 of 12 articles. Conclusion: The literature search revealed the paucity of the data. Careful switching from polypharmacy to monotherapy seems feasible in a majority of patients with schizophrenia. Assertive interventions, rather than passive educational approaches alone, appear more effective in reducing antipsychotic polypharmacy.

Original languageEnglish
Pages (from-to)215-220
Number of pages6
JournalSchizophrenia Research
Volume143
Issue number1
DOIs
Publication statusPublished - 2013 Jan

Fingerprint

Polypharmacy
Antipsychotic Agents
Schizophrenia
Physicians
PubMed
MEDLINE
Sample Size
Randomized Controlled Trials
Clinical Trials

Keywords

  • Antipsychotic
  • Intervention
  • Polypharmacy
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Interventions to reduce antipsychotic polypharmacy : A systematic review. / Tani, Hideaki; Uchida, Hiroyuki; Suzuki, Takefumi; Fujii, Yasuo; Mimura, Masaru.

In: Schizophrenia Research, Vol. 143, No. 1, 01.2013, p. 215-220.

Research output: Contribution to journalArticle

Tani, Hideaki ; Uchida, Hiroyuki ; Suzuki, Takefumi ; Fujii, Yasuo ; Mimura, Masaru. / Interventions to reduce antipsychotic polypharmacy : A systematic review. In: Schizophrenia Research. 2013 ; Vol. 143, No. 1. pp. 215-220.
@article{be7494fe8dc5438da3653ccf6286f7ef,
title = "Interventions to reduce antipsychotic polypharmacy: A systematic review",
abstract = "Background: It still remains unclear as to how to counteract antipsychotic polypharmacy that remains controversial but common. The objective of this study was to synthesize the clinical evidence to reduce antipsychotic polypharmacy (i.e. use of multiple antipsychotics) in schizophrenia. Methods: A literature search was performed to identify clinical trials that attempted to reduce antipsychotic polypharmacy in patients with schizophrenia by any form of systematic intervention using PubMed as well as MEDLINE, EMBASE, and PsycINFO (last search: June 2012). The search terms included {"}antipsychotics{"} and {"}polypharmacy{"}. Cross-referencing was also performed. Results: The literature search identified 17 studies. Only 3 studies (1 randomized controlled trial and 2 open-label trials) were found that systematically switched antipsychotic polypharmacy to monotherapy. In two of them, more than two thirds of the subjects successfully completed the switch (40/58, 69.0{\%}; 34/44, and 77.3{\%}, respectively) while less than half the subjects tolerated it in the other study (6/14 and 42.9{\%}) although the sample size was very small. On the other hand, 14 studies that examined impacts of interventions have physicians refrain from antipsychotic polypharmacy. While a modest intervention with educational approach alone was effective in three of the five articles, a more assertive intervention that directly cautioned physicians on the use of polypharmacy was effective in 10 of 12 articles. Conclusion: The literature search revealed the paucity of the data. Careful switching from polypharmacy to monotherapy seems feasible in a majority of patients with schizophrenia. Assertive interventions, rather than passive educational approaches alone, appear more effective in reducing antipsychotic polypharmacy.",
keywords = "Antipsychotic, Intervention, Polypharmacy, Schizophrenia",
author = "Hideaki Tani and Hiroyuki Uchida and Takefumi Suzuki and Yasuo Fujii and Masaru Mimura",
year = "2013",
month = "1",
doi = "10.1016/j.schres.2012.10.015",
language = "English",
volume = "143",
pages = "215--220",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Interventions to reduce antipsychotic polypharmacy

T2 - A systematic review

AU - Tani, Hideaki

AU - Uchida, Hiroyuki

AU - Suzuki, Takefumi

AU - Fujii, Yasuo

AU - Mimura, Masaru

PY - 2013/1

Y1 - 2013/1

N2 - Background: It still remains unclear as to how to counteract antipsychotic polypharmacy that remains controversial but common. The objective of this study was to synthesize the clinical evidence to reduce antipsychotic polypharmacy (i.e. use of multiple antipsychotics) in schizophrenia. Methods: A literature search was performed to identify clinical trials that attempted to reduce antipsychotic polypharmacy in patients with schizophrenia by any form of systematic intervention using PubMed as well as MEDLINE, EMBASE, and PsycINFO (last search: June 2012). The search terms included "antipsychotics" and "polypharmacy". Cross-referencing was also performed. Results: The literature search identified 17 studies. Only 3 studies (1 randomized controlled trial and 2 open-label trials) were found that systematically switched antipsychotic polypharmacy to monotherapy. In two of them, more than two thirds of the subjects successfully completed the switch (40/58, 69.0%; 34/44, and 77.3%, respectively) while less than half the subjects tolerated it in the other study (6/14 and 42.9%) although the sample size was very small. On the other hand, 14 studies that examined impacts of interventions have physicians refrain from antipsychotic polypharmacy. While a modest intervention with educational approach alone was effective in three of the five articles, a more assertive intervention that directly cautioned physicians on the use of polypharmacy was effective in 10 of 12 articles. Conclusion: The literature search revealed the paucity of the data. Careful switching from polypharmacy to monotherapy seems feasible in a majority of patients with schizophrenia. Assertive interventions, rather than passive educational approaches alone, appear more effective in reducing antipsychotic polypharmacy.

AB - Background: It still remains unclear as to how to counteract antipsychotic polypharmacy that remains controversial but common. The objective of this study was to synthesize the clinical evidence to reduce antipsychotic polypharmacy (i.e. use of multiple antipsychotics) in schizophrenia. Methods: A literature search was performed to identify clinical trials that attempted to reduce antipsychotic polypharmacy in patients with schizophrenia by any form of systematic intervention using PubMed as well as MEDLINE, EMBASE, and PsycINFO (last search: June 2012). The search terms included "antipsychotics" and "polypharmacy". Cross-referencing was also performed. Results: The literature search identified 17 studies. Only 3 studies (1 randomized controlled trial and 2 open-label trials) were found that systematically switched antipsychotic polypharmacy to monotherapy. In two of them, more than two thirds of the subjects successfully completed the switch (40/58, 69.0%; 34/44, and 77.3%, respectively) while less than half the subjects tolerated it in the other study (6/14 and 42.9%) although the sample size was very small. On the other hand, 14 studies that examined impacts of interventions have physicians refrain from antipsychotic polypharmacy. While a modest intervention with educational approach alone was effective in three of the five articles, a more assertive intervention that directly cautioned physicians on the use of polypharmacy was effective in 10 of 12 articles. Conclusion: The literature search revealed the paucity of the data. Careful switching from polypharmacy to monotherapy seems feasible in a majority of patients with schizophrenia. Assertive interventions, rather than passive educational approaches alone, appear more effective in reducing antipsychotic polypharmacy.

KW - Antipsychotic

KW - Intervention

KW - Polypharmacy

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84871937726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871937726&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2012.10.015

DO - 10.1016/j.schres.2012.10.015

M3 - Article

VL - 143

SP - 215

EP - 220

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1

ER -